NCT02584478 / 2021-003871-32: Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) |
|
|
| Active, not recruiting | 3 | 294 | Europe, US, RoW | AL3818, Anlotinib Hydrochloride, Anlotinib, Catequentinib, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan, Daily Topotecan, Weekly Topotecan, Carboplatin, Paraplatin, Taxol | Advenchen Laboratories, LLC, Advenchen Laboratories, LLC | Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Cervical Carcinoma | 10/24 | 12/24 | | |
NCT04712851: Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia |
|
|
| Recruiting | 2 | 25 | US | Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475 | Jonsson Comprehensive Cancer Center, Merck Sharp & Dohme LLC | Cervical Intraepithelial Neoplasia, Cervical Squamous Cell Carcinoma In Situ, Cervical Squamous Intraepithelial Neoplasia 2 | 01/25 | 01/26 | | |
